{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:35:59Z","timestamp":1793277359200,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The diagnosis of Dementia with Lewy Bodies (DLB) is primarily based on clinical features. The main driver of DLB is alpha-synuclein-related pathology, but cerebrovascular disease (CVD) and Alzheimer\u2019s Disease (AD) co-pathologies are often found in patients with DLB. Fluid biomarkers and magnetic resonance imaging (MRI) can provide mechanistic and diagnostic information beyond clinical features. Therefore, the aim of this study was to investigate the association of plasma biomarkers (GFAP, NfL, A\u03b242\/40, pTau231, pTau181) with MRI markers of neurodegeneration and CVD in DLB and in patients with AD as a control group. We also evaluated the ability of biomarkers and clinical features to discriminate between DLB and AD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We included 134 patients from the European DLB consortium (DLB (<jats:italic>n<\/jats:italic>\u2009=\u200992) and AD (<jats:italic>n<\/jats:italic>\u2009=\u200943)) with plasma biomarkers determined with Simoa and MRI assessed with radiological scales for medial temporal lobe atrophy (MTA), global cortical atrophy scale \u2013 frontal subscale (GCA-F), posterior atrophy (PA), and cerebrovascular disease (Fazekas scale). Associations between plasma and MRI biomarkers were assessed with the Mann-Whitney <jats:italic>U<\/jats:italic> test, and group differences and the discrimination between DLB and AD were assessed with ANCOVA, Random Forest, and ROC analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In DLB, plasma concentrations of GFAP and NfL were associated with MTA, GCA-F, and Fazekas scale; and the A\u03b242\/40 ratio was associated with PA and Fazekas. Most of these associations were not statistically significant in AD. Individually, plasma and MRI biomarkers had a limited ability to discriminate DLB from AD. Plasma biomarkers helped increase the low specificity of core clinical features from 68% up to 79%, keeping the high sensitivity of 90%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Plasma biomarkers of AD co-pathology, glial processes and unspecific neurodegeneration are associated with MRI biomarkers of atrophy and cerebrovascular disease in DLB patients. Plasma biomarkers increase the ability of core clinical features to discriminate between DLB and AD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13195-025-01848-x","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:41:09Z","timestamp":1755862869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The association between plasma and MRI biomarkers in dementia with lewy bodies"],"prefix":"10.1186","volume":"17","author":[{"given":"Carmen","family":"Pe\u00f1a-Bautista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Bolsewig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Westman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bousiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afina W","family":"Lemstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Ch\u00e1fer-Peric\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Baquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"1848_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1055\/s-0034-1381741","volume":"34","author":"M Mayo","year":"2014","unstructured":"Mayo M, Bordelon Y. Dementia with lewy bodies. Semin Neurol. 2014;34:182\u20138.","journal-title":"Semin Neurol"},{"key":"1848_CR2","doi-asserted-by":"publisher","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","volume":"10","author":"MG Erkkinen","year":"2018","unstructured":"Erkkinen MG, Kim M-O, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018;10:a033118.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1848_CR3","doi-asserted-by":"crossref","unstructured":"Vermunt L, Doelkahar BS, Peeters CFW, van de Beek M, Visser PJ, Tijms BM, et al. Dementia with lewy bodies (DLB) with amyloid co-pathology has a distinct CSF proteomics profile compared to pure DLB and alzheimer disease. Volume 17. Alzheimer\u2019s & Dementia; 2021.","DOI":"10.1002\/alz.053979"},{"key":"1848_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with lewy bodies. Neurology. 2017;89:88\u2013100.","journal-title":"Neurology"},{"key":"1848_CR5","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.3390\/ijms23126371","volume":"23","author":"O Bousiges","year":"2022","unstructured":"Bousiges O, Blanc F. Biomarkers of dementia with lewy bodies: differential diagnostic with alzheimer\u2019s disease. Int J Mol Sci. 2022;23:6371.","journal-title":"Int J Mol Sci"},{"key":"1848_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jalz.2018.09.011","volume":"15","author":"K Oppedal","year":"2019","unstructured":"Oppedal K, Ferreira D, Cavallin L, Lemstra AW, ten Kate M, Padovani A, et al. A signature pattern of cortical atrophy in dementia with lewy bodies: A study on 333 patients from the European DLB consortium. Alzheimer\u2019s Dement. 2019;15:400\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1848_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0000000000009058","volume":"94","author":"D Ferreira","year":"2020","unstructured":"Ferreira D, Nordberg A, Westman E. Biological subtypes of alzheimer disease. Neurology. 2020;94:436\u201348.","journal-title":"Neurology"},{"key":"1848_CR8","doi-asserted-by":"crossref","unstructured":"Ferreira D, Przybelski SA, Lesnick TG, Lemstra AW, Londos E, Blanc F et al. \u03b2-Amyloid and Tau biomarkers and clinical phenotype in dementia with lewy bodies. Neurology. 2020;95.","DOI":"10.1212\/WNL.0000000000010943"},{"key":"1848_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/mds.26668","volume":"31","author":"C Abdelnour","year":"2016","unstructured":"Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG, et al. Alzheimer\u2019s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Mov Disord. 2016;31:1203\u20138.","journal-title":"Mov Disord"},{"key":"1848_CR10","doi-asserted-by":"crossref","unstructured":"Irwin DJ, Xie SX, Coughlin D, Nevler N, Akhtar RS, McMillan CT et al. CSF Tau and \u03b2-amyloid predict cerebral synucleinopathy in autopsied lewy body disorders. Neurology. 2018;90.","DOI":"10.1212\/WNL.0000000000005166"},{"key":"1848_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/acn3.51253","volume":"8","author":"O Hansson","year":"2021","unstructured":"Hansson O, Cullen N, Zetterberg H, Blennow K, Mattsson-Carlgren N. Plasma phosphorylated tau181 and neurodegeneration in alzheimer\u2019s disease. Ann Clin Transl Neurol. 2021;8:259\u201365.","journal-title":"Ann Clin Transl Neurol"},{"key":"1848_CR12","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1038\/s41598-017-05390-1","volume":"7","author":"J-L Hsu","year":"2017","unstructured":"Hsu J-L, Lee W-J, Liao Y-C, Lirng J-F, Wang S-J, Fuh J-L. Plasma biomarkers are associated with agitation and regional brain atrophy in alzheimer\u2019s disease. Sci Rep. 2017;7:5035.","journal-title":"Sci Rep"},{"key":"1848_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13195-021-00802-x","volume":"13","author":"C Tissot","year":"2021","unstructured":"Tissot C, Benedet L, Therriault A, Pascoal J, Lussier TA, Saha-Chaudhuri FZ. Plasma pTau181 predicts cortical brain atrophy in aging and alzheimer\u2019s disease. Alzheimers Res Ther. 2021;13:69.","journal-title":"Alzheimers Res Ther"},{"key":"1848_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","volume":"38","author":"Z Yang","year":"2015","unstructured":"Yang Z, Wang KKW. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38:364\u201374.","journal-title":"Trends Neurosci"},{"key":"1848_CR15","doi-asserted-by":"publisher","first-page":"11624","DOI":"10.3390\/ijms241411624","volume":"24","author":"S Coppens","year":"2023","unstructured":"Coppens S, Lehmann S, Hopley C, Hirtz C. Neurofilament-Light, a promising biomarker: analytical, metrological and clinical challenges. Int J Mol Sci. 2023;24:11624.","journal-title":"Int J Mol Sci"},{"key":"1848_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","volume":"12","author":"IMW Verberk","year":"2020","unstructured":"Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, et al. Combination of plasma amyloid beta(1\u201342\/1\u201340) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12:118.","journal-title":"Alzheimers Res Ther"},{"key":"1848_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11357-023-00888-1","volume":"46","author":"ACE van Gennip","year":"2023","unstructured":"van Gennip ACE, Satizabal CL, Tracy RP, Sigurdsson S, Gudnason V, Launer LJ, et al. Associations of plasma nfl, GFAP, and t-tau with cerebral small vessel disease and incident dementia: longitudinal data of the AGES-Reykjavik study. Geroscience. 2023;46:505\u201316.","journal-title":"Geroscience"},{"key":"1848_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2022.07.008","volume":"101","author":"PC Donaghy","year":"2022","unstructured":"Donaghy PC, Firbank M, Petrides G, Lloyd J, Barnett N, Olsen K, et al. The relationship between plasma biomarkers and amyloid PET in dementia with lewy bodies. Parkinsonism Relat Disord. 2022;101:111\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"1848_CR19","doi-asserted-by":"crossref","unstructured":"Bolsewig K, van Unnik AAJM, Blujdea ER, Gonzalez MC, Ashton NJ, Aarsland D et al. Association of plasma amyloid, P-Tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with lewy bodies. Neurology. 2024;102.","DOI":"10.1212\/WNL.0000000000209418"},{"key":"1848_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","volume":"79","author":"MC Gonzalez","year":"2022","unstructured":"Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK, et al. Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with lewy bodies. JAMA Neurol. 2022;79:32.","journal-title":"JAMA Neurol"},{"key":"1848_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial Temporal lobes on MRI in probable alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1848_CR22","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00330-015-4101-9","volume":"26","author":"D Ferreira","year":"2016","unstructured":"Ferreira D, Cavallin L, Granberg T, Lindberg O, Aguilar C, Mecocci P, et al. Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. Eur Radiol. 2016;26:2597\u2013610.","journal-title":"Eur Radiol"},{"key":"1848_CR23","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1007\/s00330-011-2205-4","volume":"21","author":"ELGE Koedam","year":"2011","unstructured":"Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol. 2011;21:2618\u201325.","journal-title":"Eur Radiol"},{"key":"1848_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R. MR signal abnormalities at 1.5 T in alzheimer\u2019s dementia and normal aging. Am J Roentgenol. 1987;149:351\u20136.","journal-title":"Am J Roentgenol"},{"key":"1848_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2217\/nmt-2019-0016","volume":"9","author":"K Oppedal","year":"2019","unstructured":"Oppedal K, Borda MG, Ferreira D, Westman E, Aarsland D. European Dlb consortium: diagnostic and prognostic biomarkers in dementia with lewy bodies, a multicenter international initiative. Neurodegener Dis Manag. 2019;9:247\u201350.","journal-title":"Neurodegener Dis Manag"},{"key":"1848_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"1848_CR27","doi-asserted-by":"publisher","first-page":"46263","DOI":"10.1038\/srep46263","volume":"7","author":"D Ferreira","year":"2017","unstructured":"Ferreira D, Verhagen C, Hern\u00e1ndez-Cabrera JA, Cavallin L, Guo C-J, Ekman U, et al. Distinct subtypes of alzheimer\u2019s disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Sci Rep. 2017;7:46263.","journal-title":"Sci Rep"},{"key":"1848_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/joim.12358","volume":"278","author":"D Ferreira","year":"2015","unstructured":"Ferreira D, Cavallin L, Larsson E-M, Muehlboeck J, \u2010S., Mecocci P, Vellas B, et al. Practical cut\u2010offs for visual rating scales of medial temporal, frontal and posterior atrophy in <\u2009scp\u2009>\u2009a\u2009lzheimer\u2019s disease and mild cognitive impairment. J Intern Med. 2015;278:277\u201390.","journal-title":"J Intern Med"},{"key":"1848_CR29","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/alz.13571","volume":"20","author":"J Oltra","year":"2024","unstructured":"Oltra J, Habich A, Schwarz CG, Nedelska Z, Przybelski SA, Inguanzo A, et al. Sex differences in brain atrophy in dementia with lewy bodies. Alzheimer\u2019s Dement. 2024;20:1815\u201326.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1848_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jns.2017.12.018","volume":"385","author":"H Joki","year":"2018","unstructured":"Joki H, Higashiyama Y, Nakae Y, Kugimoto C, Doi H, Kimura K, et al. White matter hyperintensities on MRI in dementia with lewy bodies, parkinson\u2019s disease with dementia, and alzheimer\u2019s disease. J Neurol Sci. 2018;385:99\u2013104.","journal-title":"J Neurol Sci"},{"key":"1848_CR31","first-page":"19","volume":"1","author":"T Maciej","year":"2014","unstructured":"Maciej T, Ewa T. The need to report effect size estimates revisited.an overview of some recommended measures of effect size. Trends Sport Sci. 2014;1:19\u201325.","journal-title":"Trends Sport Sci"},{"key":"1848_CR32","volume-title":"Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease","author":"JR Chong","year":"2023","unstructured":"Chong JR, Hilal S, Ashton NJ, Karikari TK, Reilhac A, Vrooman H, et al. Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease. Volume 15. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring; 2023."},{"key":"1848_CR33","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1515\/cclm-2023-0036","volume":"61","author":"B Arslan","year":"2023","unstructured":"Arslan B, Zetterberg H. Neurofilament light chain as neuronal injury marker \u2013 what is needed to facilitate implementation in clinical laboratory practice? Clin Chem Lab Med (CCLM). 2023;61:1140\u20139.","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"1848_CR34","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1002\/alz.13898","volume":"20","author":"P Shahim","year":"2024","unstructured":"Shahim P, Pham DL, van der Merwe AJ, Moore B, Chou Y, Lippa SM, et al. Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI. Alzheimer\u2019s Dement. 2024;20:4663\u201376.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1848_CR35","doi-asserted-by":"publisher","first-page":"104854","DOI":"10.1016\/j.msard.2023.104854","volume":"77","author":"C Ammitzb\u00f8ll","year":"2023","unstructured":"Ammitzb\u00f8ll C, Dyrby TB, B\u00f6rnsen L, Schreiber K, Ratzer R, Romme Christensen J, et al. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis. Mult Scler Relat Disord. 2023;77:104854.","journal-title":"Mult Scler Relat Disord"},{"key":"1848_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/brainsci14030272","volume":"14","author":"C Gallingani","year":"2024","unstructured":"Gallingani C, Carbone C, Tondelli M, Zamboni G. Neurofilaments light chain in neurodegenerative dementias: A review of imaging correlates. Brain Sci. 2024;14:272.","journal-title":"Brain Sci"},{"key":"1848_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/brainsci14030269","volume":"14","author":"Q Kong","year":"2024","unstructured":"Kong Q, Xie X, Wang Z, Zhang Y, Zhou X, Wu L, et al. Correlations of plasma biomarkers and imaging characteristics of cerebral small vessel disease. Brain Sci. 2024;14:269.","journal-title":"Brain Sci"},{"key":"1848_CR38","doi-asserted-by":"crossref","unstructured":"Edwards NC, Lao PJ, Alshikho MJ, Ericsson OM, Rizvi B, Petersen ME et al. Cerebrovascular disease drives alzheimer plasma biomarker concentrations in adults with down syndrome. Preprint medRxiv. 2023.","DOI":"10.1101\/2023.11.28.23298693"},{"key":"1848_CR39","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.neurobiolaging.2015.03.007","volume":"36","author":"Z Nedelska","year":"2015","unstructured":"Nedelska Z, Schwarz CG, Boeve BF, Lowe VJ, Reid RI, Przybelski SA, et al. White matter integrity in dementia with lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiol Aging. 2015;36:2010\u20137.","journal-title":"Neurobiol Aging"},{"key":"1848_CR40","doi-asserted-by":"publisher","first-page":"102333","DOI":"10.1016\/j.nicl.2020.102333","volume":"27","author":"C Abdelnour","year":"2020","unstructured":"Abdelnour C, Ferreira D, Oppedal K, Cavallin L, Bousiges O, Wahlund LO, et al. The combined effect of amyloid-\u03b2 and Tau biomarkers on brain atrophy in dementia with lewy bodies. Neuroimage Clin. 2020;27:102333.","journal-title":"Neuroimage Clin"},{"key":"1848_CR41","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1002\/alz.14225","volume":"20","author":"A Pichet Binette","year":"2024","unstructured":"Pichet Binette A, Mammana A, Wisse L, Rossi M, Strandberg O, Smith R, et al. Associations between misfolded alpha-synuclein aggregates and alzheimer\u2019s disease pathology in vivo. Alzheimer\u2019s Dement. 2024;20:7624\u201334.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1848_CR42","doi-asserted-by":"crossref","unstructured":"Wan M, Liu H, Liu X, Zhang W, Xiao X, Zhang S et al. Associations of multiple visual rating scales based on structural magnetic resonance imaging with disease severity and cerebrospinal fluid biomarkers in patients with alzheimer\u2019s disease. Front Aging Neurosci. 2022;14.","DOI":"10.3389\/fnagi.2022.906519"},{"key":"1848_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13195-017-0328-9","volume":"9","author":"I Bos","year":"2017","unstructured":"Bos I, Verhey FR, Ramakers IHGB, Jacobs HIL, Soininen H, Freund-Levi Y, et al. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimers Res Ther. 2017;9:101.","journal-title":"Alzheimers Res Ther"},{"key":"1848_CR44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/sj.mp.4001379","volume":"8","author":"EM Hol","year":"2003","unstructured":"Hol EM, Roelofs RF, Moraal E, Sonnemans MAF, Sluijs JA, Proper EA, et al. Neuronal expression of GFAP in patients with alzheimer pathology and identification of novel GFAP splice forms. Mol Psychiatry. 2003;8:786\u201396.","journal-title":"Mol Psychiatry"},{"key":"1848_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","volume":"14","author":"S Baiardi","year":"2022","unstructured":"Baiardi S, Quadalti C, Mammana A, Dellavalle S, Zenesini C, Sambati L, et al. Diagnostic value of plasma p-tau181, nfl, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther. 2022;14:153.","journal-title":"Alzheimers Res Ther"},{"key":"1848_CR46","doi-asserted-by":"crossref","unstructured":"Thijssen EH, Verberk IMW, Kindermans J, Abramian A, Vanbrabant J, Ball AJ, et al. Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Volume 14. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring.; 2022.","DOI":"10.1002\/dad2.12285"},{"key":"1848_CR47","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/mds.28994","volume":"37","author":"AJ Thomas","year":"2022","unstructured":"Thomas AJ, Hamilton CA, Heslegrave A, Barker S, Durcan R, Lawley S, et al. A longitudinal study of Plasma\u2009<\u2009scp\u2009>\u2009pTau181\u2009in mild cognitive impairment with lewy bodies and alzheimer\u2019s disease. Mov Disord. 2022;37:1495\u2013504.","journal-title":"Mov Disord"},{"key":"1848_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1017\/S1041610212001214","volume":"25","author":"J O\u2019Donovan","year":"2013","unstructured":"O\u2019Donovan J, Watson R, Colloby SJ, Firbank MJ, Burton EJ, Barber R, et al. Does posterior cortical atrophy on MRI discriminate between alzheimer\u2019s disease, dementia with lewy bodies, and normal aging? Int Psychogeriatr. 2013;25:111\u20139.","journal-title":"Int Psychogeriatr"},{"key":"1848_CR49","doi-asserted-by":"crossref","unstructured":"Zhu H, Lu H, Wang F, Liu S, Shi Z, Gan J et al. Characteristics of cortical atrophy and white matter lesions between dementia with lewy bodies and alzheimer\u2019s disease: A Case-Control study. Front Neurol. 2022;12.","DOI":"10.3389\/fneur.2021.779344"},{"key":"1848_CR50","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","volume":"89","author":"G Rizzo","year":"2018","unstructured":"Rizzo G, Arcuti S, Copetti M, Alessandria M, Savica R, Fontana A, et al. Accuracy of clinical diagnosis of dementia with lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89:358\u201366.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1848_CR51","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1212\/WNL.0b013e31822c9148","volume":"77","author":"TJ Ferman","year":"2011","unstructured":"Ferman TJ, Boeve BF, Smith GE, Lin S-C, Silber MH, Pedraza O, et al. Inclusion of RBD improves the diagnostic classification of dementia with lewy bodies. Neurology. 2011;77:875\u201382.","journal-title":"Neurology"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01848-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01848-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:38:37Z","timestamp":1757421517000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01848-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01848-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent on participation was obtained from all patients or a surrogate according to the Declaration of Helsink, and the study was approved by the ethical committee of each participating center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D. Aarsland reports receiving research support and\/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals, Biogen, Evonik, Sanofi, Roche, and GE Health and serving as a paid consultant for H. Lundbeck, Eisai, Heptares, and Mentis Cura. H. Zetterberg has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). C.E. Teunissen has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, PeopleBio, Roche, Siemens, Toyama, and Vivoryon. She is an editor of Alzheimer Research and Therapy, and serves on editorial boards of Medidact Neurologie\/Springer, and Neurology: Neuroimmunology & Neuroinflammation. She had speaker contracts for Roche, Grifols, Novo Nordisk. D. Ferreira consults for BioArctic and has received honoraria from Esteve. The remaining co-authors report no disclosures relevant to the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}